Actively Recruiting
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Led by Beihua Kong · Updated on 2023-04-25
132
Participants Needed
1
Research Sites
787 weeks
Total Duration
On this page
Sponsors
B
Beihua Kong
Lead Sponsor
H
Huazhong University of Science and Technology
Collaborating Sponsor
AI-Summary
What this Trial Is About
Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed ovarian malignant sex cord-stromal tumor patients after surgery.
CONDITIONS
Official Title
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female Chinese women aged 14 to 65 years
- Histologically confirmed ovarian stromal tumor of specified cell types including granulosa cell tumor, granulosa cell-theca cell tumor, Sertoli-Leydig cell tumor, steroid (lipid) cell tumor, gynandroblastoma, unclassified sex cord-stromal tumor, or sex cord tumor with annular tubules
- Newly diagnosed stage IIA-IVB disease
- Surgery for diagnosis, staging, or cytoreduction performed within the past 8 weeks
- May or may not have measurable residual disease
- Laboratory tests meeting specified minimum blood counts and liver and kidney function limits
- Karnofsky performance score of 60 or higher
- Ability to provide written informed consent
You will not qualify if you...
- Severe or uncontrolled internal disease preventing surgery or chemotherapy
- History of organ transplantation or immune diseases
- History of serious mental illness or brain dysfunction
- History of drug abuse
- Presence of other malignancies
- Participation in other clinical trials
- Unable or unwilling to sign informed consent
- Unable or unwilling to comply with the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qilu Hospital of Shandong University
Jinan, Shandong, China
Actively Recruiting
Research Team
B
Beihua Kong, MD. PhD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here